Insider Selling: Evolus, Inc. (NASDAQ:EOLS) CFO Sells 3,276 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Evolus Price Performance

Shares of EOLS stock opened at $15.27 on Thursday. The stock has a market cap of $963.38 million, a price-to-earnings ratio of -14.54 and a beta of 1.30. The business’s fifty day moving average is $13.44 and its 200 day moving average is $13.00. Evolus, Inc. has a twelve month low of $7.44 and a twelve month high of $16.29. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $66.91 million during the quarter, compared to the consensus estimate of $65.06 million. Research analysts expect that Evolus, Inc. will post -0.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Evolus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC bought a new stake in Evolus in the second quarter worth $43,000. Quarry LP bought a new stake in Evolus in the second quarter worth $54,000. Tradition Wealth Management LLC boosted its holdings in Evolus by 44.8% in the fourth quarter. Tradition Wealth Management LLC now owns 8,000 shares of the company’s stock worth $84,000 after acquiring an additional 2,475 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Evolus by 65.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,969 shares of the company’s stock worth $154,000 after acquiring an additional 4,355 shares in the last quarter. Finally, Sierra Summit Advisors LLC bought a new stake in Evolus in the fourth quarter worth $119,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on EOLS shares. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Evolus in a research note on Thursday, August 1st. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Evolus in a research note on Thursday, August 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research note on Monday.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.